BioNote, Inc. (KRX:377740)
South Korea · Delayed Price · Currency is KRW 4,570.00
+15.00 (0.33%)
At close: Aug 3, 2026
BioNote Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 122,445 | 118,324 | 102,780 | 90,081 | 479,657 | 622,355 |
Revenue Growth | 15.60% | 15.12% | 14.10% | -81.22% | -22.93% | -1.45% |
Gross Profit Gross Profit Growth | 69,603 | 65,675 | 50,973 | -11,659 | 340,471 | 512,003 |
Operating Income Operating Income Growth | 18,472 | 16,809 | 12,218 | -47,168 | 295,410 | 468,748 |
Net Income Net Income Growth | -50,226 | -87,498 | 55,261 | -20,497 | 307,798 | 676,601 |
Earnings Per Share EPS Growth | -497.08 | -865.27 | 542.00 | -201.00 | 3264.00 | 7222.00 |
EPS Growth | - | - | - | - | -54.81% | 27.91% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 363,351 | 339,813 | 405,416 | 400,168 | 721,461 | 488,612 |
Total Debt Total Debt Growth | 3,335 | 3,651 | 3,931 | 4,928 | 1,362 | 769.65 |
Net Cash (Debt) Net Cash Growth | 360,016 | 336,162 | 401,485 | 395,240 | 720,100 | 487,842 |
Net Cash Growth | -6.29% | -16.27% | 1.58% | -45.11% | 47.61% | 140.00% |
Net Cash Per Share Net Cash Per Share Growth | 3561.70 | 3321.22 | 3937.74 | 3875.76 | 7637.27 | 5206.96 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 23,882 | 14,381 | 57,917 | -4,194 | 249,100 | 537,392 |
Capital Expenditures CapEx Growth | -5,401 | -8,111 | -10,462 | -3,963 | -42,266 | -51,425 |
Free Cash Flow Free Cash Flow Growth | 18,482 | 6,270 | 47,454 | -8,156 | 206,834 | 485,966 |
Free Cash Flow Growth | -46.16% | -86.79% | - | - | -57.44% | 127.91% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 56.84% | 55.51% | 49.59% | -12.94% | 70.98% | 82.27% |
Operating Margin | 15.09% | 14.21% | 11.89% | -52.36% | 61.59% | 75.32% |
Pretax Margin | -42.49% | -74.01% | 71.34% | -121.55% | 86.47% | 139.77% |
Profit Margin | -41.02% | -73.95% | 53.77% | -22.75% | 64.17% | 108.72% |
FCF Margin | 15.09% | 5.30% | 46.17% | -9.05% | 43.12% | 78.09% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 8.70 | - | 2.84 | - |
P/FCF Ratio | 24.94 | 88.43 | 10.13 | - | 4.23 | - |
PS Ratio | 3.76 | 4.69 | 4.68 | 4.81 | 1.82 | - |